Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Antiviral Therapeutics

Cocrystal Pharma has received IRB approval from Emory University School of Medicine for its clinical-stage biotechnology company. The company is developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. Its candidates under development include CC-42344 for pandemic and seasonal influenza A, CDI-988 for SARS-CoV-2, and CC-31244 for HCV treatment.